Elasmogen announces a panel of novel, potent, anti-COVID-19 therapeutic candidates identified through collaboration with U.S. research partners
The Pharma Data
JANUARY 24, 2021
The newly identified anti-COVID-19 Spike protein VNARs block infection of the virus (in live viral assays) at doses as low as 200 pM, equivalent to the best reported antibodies and much better than many. It is therefore vital that we continue with drug discovery approaches in parallel with the global vaccination role out.”
52 
Let's personalize your content